Login to Your Account



Other News To Note


Friday, June 29, 2012

• InterMune Inc., of Brisbane, Calif., said the Swedish Dental and Pharmaceutical Benefits Agency included Esbriet (pirfenidone) on the country's list of reimbursed drugs, making Esbriet the first therapeutic treatment for idiopathic pulmonary fibrosis to be reimbursed in Sweden.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription